Taking a very different approach to the treatment of cancer with a focus on ability to engage multi-faceted anti-tumor response, Khloris Biosciences Inc is structured around development of a iPSC-derived whole cell vaccine. Fundamentally differentiated from previous cancer vaccinations, iPSC vaccination combines key mechanistic elements to boost anti-tumor immunity. Presenting a broad spectrum of oncofetal and other cancer-related antigens, iPSC vaccination fully mobilizes the immune system. Khloris is also developing iPSC-derived cardiomyocytes as a novel cell therapy treatment for patients with cardiovascular diseases.
